Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
Delayed Quote. Delayed Nasdaq - 06/17 04:00:00 pm
67.1 USD   +1.12%
06/17GILEAD SCIENCES : A new era for Gilead
AQ
06/13Health Care Down on Cyclical Bias -- Health Care Roundup
DJ
06/13GILEAD SCIENCES : Ex-dividend day for
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201620172018201920202021
Sales30 39026 10722 12722 04822 40022 357
EBITDA20 34716 40511 71612 96413 00912 844
Operating profit (EBIT)20 03316 03111 41111 43911 48611 242
Pre-Tax Profit (EBT)------
Net income13 5014 6285 4556 9546 9977 190
P/E ratio7,2020,415,012,011,911,4
EPS ( $ )9,943,514,175,445,515,74
Dividend per Share ( $ )1,842,082,282,532,722,80
Yield2,57%2,90%3,65%3,87%4,16%4,29%
Reference price ( $ )71.6171.6462.5565.3565.3565.35
Announcement Date02/07/2017
09:01pm
02/06/2018
09:01pm
02/04/2019
09:01pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201620172018201920202021
Debt-8 0329 3825 969--
Finance32 380---1 047246
Operating income (EBITDA)20 34716 40511 71612 96413 00912 844
Leverage
(Debt/EBITDA)
-0,49x0,80x0,46x--
Capital Expenditure748590924772780755
Book Value Per Share (BVPS)14,6 $15,7 $16,7 $18,7 $20,0 $20,4 $
Cash Flow per Share12,3 $9,02 $6,42 $7,16 $7,58 $7,85 $
Announcement Date02/07/2017
09:01pm
02/06/2018
09:01pm
02/04/2019
09:01pm
---
Balance Sheet Analysis
Assessed data source :
© 2019 Thomson Reuters
Financial Ratios

Size 2019e 2020e
Capitalization 83 096 M$ -
Entreprise Value (EV) 89 065 M$ 82 050 M$
Valuation 2019e 2020e
P/E ratio (Price / EPS) 12,0x 11,9x
Capitalization / Revenue 3,77x 3,71x
EV / Revenue 4,04x 3,66x
EV / EBITDA 6,87x 6,31x
Yield (DPS / Price) 3,87% 4,16%
Price to book (Price / BVPS) 3,49x 3,26x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) 51,9% 51,3%
operating Leverage (Delta EBIT / Delta Sales) - 0,26x
Net Margin (Net Profit / Revenue) 31,5% 31,2%
ROA (Net Profit / Asset) 13,8% 13,8%
ROE (Net Profit / Equities) 50,7% 34,0%
Rate of Dividend 46,5% 49,4%
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   3,50% 3,48%
Cash Flow / Sales 41,3% 43,0%
Capital Intensity (Assets / Sales) 2,28x 2,27x
Financial Leverage (Net Debt / EBITDA) 0,46x -0,08x
EPS & Dividend